Clinical trials: Solid Tumor, completed
Unspecified Adult Solid Tumor, Protocol Specific
Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00084513
- Testing
- trastuzumab, imatinib mesylate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fox Chase Cancer Center
Childhood Solid Tumor
Comparing the Impact of Cancer on Quality of Life Between Survivors of Childhood Solid Tumors and Leukemia
The aim of the study is to examine the impact of cancer and treatment-related effects on the physical and psychosocial well-being and quality of life among Hong Kong Chinese survivors of childhood solid tumors.
- Trial name
- NCT03430752
- Testing
- questionnaires
- Where
- Hong Kong
- Volunteers
- 135 people
- Sponsor
- The University of Hong Kong
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Positive Activities Intervention to Improve Quality of Life in Collectivist Culture Cancer Patients and Their Caregivers
This clinical trial studies the feasibility of two positive activities in improving quality of life in collectivist culture cancer patients and their caregivers.
- Trial name
- NCT04810052
- Testing
- Behavioral Intervention, Interview, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors
Over the last decade, improvements in the investigators' understanding of the molecular basis of cancer have led to the clinical development of protein kinase inhibitors, which target pivotal molecules involved in intracellular…
- Trial name
- NCT00984425
- Testing
- Lapatinib and Sorafenib
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Istituto Clinico Humanitas
Solid Tumors
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors
PI3K signaling is a hallmark of many cancers. Subsets of cancers become dependent on PI3K pathway signaling as a result of mutations of the PIK3CA gene itself or of regulators of PI3K (e.g. PTEN, HER2).
- Trial name
- NCT02439489
- Testing
- BKM120-CIS, BKM120-CARBO
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Fondazione Michelangelo
Neoplasms
BIBW 2992 in Patients With Advanced Solid Tumors
The primary objective was to collect safety data for BIBW 2992.
- Trial name
- NCT02171650
- Testing
- BIBW 2992
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced Solid Tumor
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
This is an open-label, multicenter, Phase 1a study to evaluate the safety, tolerability, PK and preliminary efficacy of AN2025 and AN0025 in double or triple combination treatments with Atezolizumab in patients with locally…
- Trial name
- NCT04975958
- Testing
- AN2025, AN0025, Atezolizumab 1200 mg in 20 ML Injection
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Advanced Solid Tumors
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, drug levels, immunogenicity and preliminary efficacy of BMS-986213 (nivolumab-relatlimab fixed-dose combination) in Chinese participants with advanced solid tumors.
- Trial name
- RELATIVITY 059 (NCT05134948)
- Testing
- BMS-986213
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Bristol-Myers Squibb
Brain Metastases From Solid Tumors
131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors
The aim of this Proof of Concept study is to determine the therapeutic potential of the L19SIP antibody, labeled with the radionuclide 131I in combination with external beam radiation, for the treatment of patients with multiple…
- Trial name
- NCT01125085
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
- Where
- 10 sites in Italy, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Philogen S.p.A.
Unspecified Adult Solid Tumor, Protocol Specific
KRN5500 in Treating Patients With Solid Tumors
Phase I trial to study the effectiveness of KRN5500 in treating patients who have solid tumors. Drugs used in chemotherapy, such as KRN5500, work in different ways to stop cancer cells from dividing so they stop growing or die
- Trial name
- NCT00017238
- Testing
- KRN5500, pharmacological study
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors
The purpose of this study is to determine whether IHL-305 (irinotecan liposome injection) is safe and effective in the treatment of advanced solid tumors.
- Trial name
- NCT00364143
- Testing
- IHL-305 (irinotecan liposome injection)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Yakult Honsha Co., LTD
Advanced or Metastatic Solid Tumors
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors.
- Trial name
- NCT04381650
- Testing
- TAK-981, Pembrolizumab
- Where
- 52 sites in United States, Brazil and 7 more
- Volunteers
- 161 people
- Sponsor
- Takeda
Solid Tumor Malignancy, Hematologic Malignancy
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
Background: Coronavirus disease (COVID-19) is a viral infection. It has spread rapidly across the globe. It has overwhelmed health systems.
- Conditions
- Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma
- Trial name
- NCT04847050
- Testing
- Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Calcitriol may help tumor cells develop into normal cells.
- Trial name
- NCT00084708
- Testing
- calcitriol, dexamethasone, gefitinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Roswell Park Cancer Institute
Post-solid Organ Transplant, Skin Neoplasms
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
This is a double blind, placebo controlled study of 52 patients who are at least one-year post-solid organ transplant. Subjects will receive either 12 months of DFMO or a placebo.
- Trial name
- NCT00204789
- Testing
- Difluoromethylornithine
- Volunteers
- 52 people
- Sponsor
- University of Wisconsin, Madison
Solid Tumors
A Study of LY2523355 in Patients With Solid Cancer
The primary objective of this study is to examine a recommended dose for subsequent phase trial(s), by the observation of the safety and toxicity profiles of LY2523355 in patients with advanced and/or metastatic cancer.
- Trial name
- 2523355-001 (NCT01358019)
- Testing
- LY2523355
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Advanced Solid Tumors, Lymphoma
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
This study is being conducted to evaluate the safety profile and the Maximum Tolerated Dose (MTD) of TAK-901 in adult patients with advanced solid tumors or lymphoma.
- Trial name
- NCT00935844
- Testing
- TAK-901
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hepatocellular Carcinoma (HCC), Solid Tumors
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
Researchers are studying a new potential treatment for liver cancer or other select solid cancers. To do this, researchers have developed a protein, called a monoclonal antibody, which can find and attach itself to another…
- Trial name
- NCT06345001
- Testing
- BAY3630942, BAY3547922
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Bayer
Solid Tumors
Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors
The primary objective of this study is: Determine the safety, tolerability, maximum tolerated dose (MTD) or recommended Phase II dose (RP2D) of BAY 1436032 in patients with isocitrate dehydrogenase-1 (IDH1)-R132X-mutant advanced…
- Trial name
- NCT02746081
- Testing
- BAY1436032
- Where
- 13 sites in United States, Denmark and 2 more
- Volunteers
- 81 people
- Sponsor
- Bayer
Unspecified Adult Solid Tumor, Protocol Specific
VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of VX-853 in treating patients who have solid tumors who…
- Trial name
- NCT00004030
- Testing
- VX-853, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Georgetown University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.